ZyVersa Therapeutics, Inc. (ZVSA)
OTCMKTS
· Delayed Price · Currency is USD
0.1508
+0.0006 (0.40%)
At close: Aug 14, 2025
ZyVersa Therapeutics Employees
ZyVersa Therapeutics had 7 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,184,457
Market Cap
1.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
ZyVersa Therapeutics News
- 1 day ago - ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression - GlobeNewsWire
- 2 days ago - ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones - GlobeNewsWire
- 25 days ago - ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress - GlobeNewsWire
- 5 weeks ago - Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? - Benzinga
- 5 weeks ago - ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds - GlobeNewsWire
- 5 weeks ago - ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis - GlobeNewsWire
- 7 weeks ago - ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) - GlobeNewsWire
- 7 weeks ago - ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200 - GlobeNewsWire